文献速递白血病造血干细胞移植与细胞治疗

优化年轻与老年急性淋巴细胞白血病的治疗:新药与演变中的范式

Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
PubMed 文献 · Leukemia · 2021-06-25

综述讨论过去十年急性淋巴细胞白血病(ALL)治疗范式的快速演变。随着抗CD22抗体药物偶联物、CD3-CD19双特异性T细胞衔接抗体、CD19嵌合抗原受体T细胞疗法及强效BCR-ABL1酪氨酸激酶抑制剂的出现,年轻与老年ALL患者的前景显著改善。文章聚焦一线与挽救治疗中的新联合方案,并探讨最佳组合顺序、前线方案整合及造血干细胞移植的角色。

要点

  • 抗CD22抗体药物偶联物、CD3-CD19双特异性抗体、CD19 CAR-T及强效BCR-ABL1抑制剂显著改善ALL前景。
  • 新药带来最佳组合与顺序、前线方案整合及造血干细胞移植角色等关键问题。
  • 综述聚焦一线与挽救治疗中形成新标准治疗的新型联合方案。

核心结论

  • 新型药物显著改善了年轻与老年ALL患者的前景,治疗范式正在快速演变。

研究设计与样本

  • 综述,讨论ALL治疗中快速演变的范式,涵盖已确立的有效方案及正在临床试验中评估的新疗法。

主要发现

  • 抗CD22抗体药物偶联物、CD3-CD19双特异性T细胞衔接抗体、CD19 CAR-T疗法及强效BCR-ABL1酪氨酸激酶抑制剂的出现使ALL前景显著改善。
  • 高效药物的可用性引发了关于最佳组合与顺序、前线方案整合及造血干细胞移植角色等重要问题。

关键数值与推荐

  • 综述聚焦一线与挽救治疗中新型联合方案,这些方案正在形成ALL治疗的新标准治疗。

临床怎么用

  • 临床需关注新药在一线与挽救治疗中的联合方案,并综合考虑组合顺序、前线整合及移植时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of ALL in both younger and older adults has substantially improved. The availability of highly effective drugs raised important questions concerning the optimal combination and sequence of these agents, their incorporation into frontline regimens, and the role of hematopoietic stem cell transplantation. In this review, we discuss the rapidly evolving paradigms in the treatment of ALL, highlighting both established and effective regimens, as well as promising new therapies that are being evaluated in ongoing clinical trials. We specifically focus on novel combination regimens in both the frontline and salvage settings that are leading to new standards of care in the treatment of ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Short NJ, Kantarjian H, Jabbour E, et al. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021. PMID: 34172894. doi:10.1038/s41375-021-01277-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。